Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus brevis NES-428
- Development stage
- Preclinical
- Lead developer
- Essex Bio-Technology
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus brevis NES-428 is a novel probiotic bacterial strain isolated from kimchi, currently under preclinical investigation by EsgelBio Co. and Korea University for the treatment of autoimmune hyperthyroidism, specifically Graves' disease. The strain acts as an immunomodulator by shifting the Th1/Th2 cytokine balance; it downregulates pro-inflammatory Th1 cytokines such as interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) while upregulating anti-inflammatory Th2 cytokines like interleukin-4 (IL-4). In murine models of Graves' disease, oral administration of NES-428 has demonstrated the ability to reduce serum thyroxine (T4) levels, restore body weight gain, and normalize thyroid follicular architecture. The strain shares 99% 16S-rRNA identity with Lactobacillus brevis reference strains.
- Other names
- Lactobacillus brevis NES-428
02
Targets
IL-2 (Interleukin 2)IL-4 (Interleukin 4)IFNG (Interferon gamma)
Beyond the preview
Go deeper on Lactobacillus brevis NES-428.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus brevis NES-428.